Angiopoietin-2 and angiopoietin-like 4 protein provide prognostic information in patients with suspected acute coronary syndrome
Angiopoietin-2 and angiopoietin-like 4 protein provide prognostic information in patients with suspected acute coronary syndrome
复制标题
DOI：
10.1111/joim.13339
复制
发表时间：
2021-07-08
影响因子：
11.1
通讯作者：
Nilsen, Dennis W. T.
中科院分区：
文献类型：
--
作者：
Aarsetoy, Reidun;Ueland, Thor;Nilsen, Dennis W. T.
血管生成素-2（ANGPT 2）和血管生成素样蛋白4（ANGPTL 4）的血浆水平反映了心血管疾病的不同病理生理学方面。我们在挪威疑似急性冠状动脉综合征（ACS）住院患者队列（n = 871）中评估了其与结局的相关性，并在类似的阿根廷队列（n = 982）中验证了我们的结果。方法以24个月内全因死亡率、心源性死亡率和60个月内全因死亡率为因变量，分别对ANGPT 2和ANGPTL 4拟合考克斯回归模型，校正传统的心血管危险因素。结果在24个月的随访中，138名挪威人（15.8%）和119名阿根廷人（12.1%）死亡，其中分别有86名和66名死亡被归类为心源性死亡。在60个月时，分别有259例（29.7%）和173例（17.6%）患者死亡。ANGPT 2与两个队列24个月时的全因死亡率独立相关[风险比（HR）1.27（挪威的95%置信区间（CI），1.08-1.50），HR 1.57（阿根廷的95% CI，1.27-1.95）]，60个月时的结果相似[HR 1.19（95% CI，1.05-1.35）（挪威）和HR 1.56（95% CI，1.30-1.88）（阿根廷）]，并且在阿根廷人群中也与心源性死亡显著相关[HR 1.51（95% CI，1.14-2.00）]。ANGPTL 4与阿根廷队列24个月[HR 1.39（95% CI，1.15-1.68）]和60个月[HR 1.43（95% CI，1.23-1.67）]的全因死亡率显著相关，加强了挪威人群的趋势。结论ANGPT 2和ANGPTL 4与两大洲相似ACS患者队列的结局显著相关。临床试验注册ClinicalTrials.gov标识符：NCT 00521976。ClinicalTrials.gov标识符：NCT 01377402。
Background Plasma levels of angiopoietin-2 (ANGPT2) and angiopoietin-like 4 protein (ANGPTL4) reflect different pathophysiological aspects of cardiovascular disease. We evaluated their association with outcome in a hospitalized Norwegian patient cohort (n = 871) with suspected acute coronary syndrome (ACS) and validated our results in a similar Argentinean cohort (n = 982). Methods A cox regression model, adjusting for traditional cardiovascular risk factors, was fitted for ANGPT2 and ANGPTL4, respectively, with all-cause mortality and cardiac death within 24 months and all-cause mortality within 60 months as the dependent variables. Results At 24 months follow-up, 138 (15.8%) of the Norwegian and 119 (12.1%) of the Argentinian cohort had died, of which 86 and 66 deaths, respectively, were classified as cardiac. At 60 months, a total of 259 (29.7%) and 173 (17.6%) patients, respectively, had died. ANGPT2 was independently associated with all-cause mortality in both cohorts at 24 months [hazard ratio (HR) 1.27 (95% confidence interval (CI), 1.08-1.50) for Norway, and HR 1.57 (95% CI, 1.27-1.95) for Argentina], with similar results at 60 months [HR 1.19 (95% CI, 1.05-1.35) (Norway), and HR 1.56 (95% CI, 1.30-1.88) (Argentina)], and was also significantly associated with cardiac death [HR 1.51 (95% CI, 1.14-2.00)], in the Argentinean population. ANGPTL4 was significantly associated with all-cause mortality in the Argentinean cohort at 24 months [HR 1.39 (95% CI, 1.15-1.68)] and at 60 months [HR 1.43 (95% CI, 1.23-1.67)], enforcing trends in the Norwegian population. Conclusions ANGPT2 and ANGPTL4 were significantly associated with outcome in similar ACS patient cohorts recruited on two continents. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00521976. ClinicalTrials.gov Identifier: NCT01377402.